Related Experiment Video
Updated: Aug 8, 2026
03:51
Treatment of Ejaculatory Duct Obstruction by Seminal Vesiculoscopy Assisted Flow Modification
Published on: December 8, 2023
[Treatment of erectile dysfunction with vacuum devices]
C Núñez Mora1, E Ríos González, L Martínez-Piñeiro Lorenzo
1Servicio de Urología, Hospital Universitario La Paz, Universidad Autónoma, Madrid.
Archivos Espanoles De Urologia
|February 24, 2001
Summary
Vacuum constriction devices offer an alternative for erectile dysfunction (ED) treatment when oral therapies fail. While effective for many, common side effects like pain and lack of efficacy can lead to discontinuation.
Area of Science:
- Urology
- Andrology
- Sexual Medicine
Context:
- Erectile dysfunction (ED) significantly impacts quality of life and relationships.
- Vacuum constriction devices (VCDs) represent a non-pharmacological treatment option for ED.
- Understanding long-term outcomes and patient satisfaction with VCDs is crucial for clinical guidance.
Purpose:
- To evaluate the effectiveness, side effects, and patient/partner satisfaction with vacuum devices in treating erectile dysfunction.
- To identify patient characteristics and reasons for discontinuation of VCD therapy.
Summary:
- A survey of 150 patients using VCDs for ED revealed that 63.3% achieved erections in over half of attempts.
- Mean treatment duration was 34.6 months, with common side effects including pain and ecchymosis.
- Discontinuation (48 patients) was primarily due to lack of efficacy, partner refusal, or pain, with a mean follow-up of 10.8 months for discontinuers.
Impact:
- VCDs are a viable alternative to intracavernosal therapy for ED when oral treatments are ineffective or contraindicated.
- Ideal candidates for VCDs include men with stable partners and ED caused by venous leakage or mild arterial insufficiency.
- This study highlights the importance of patient selection and managing expectations to improve long-term VCD adherence.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:17Male Sexual Response: Erection & Ejaculation
Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
01:26Varicose Veins II: Diagnostic Studies and Interprofessional Care
Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...